Impact of Statin Use on Lipid Levels in Statin-naive Patients with Rheumatoid Arthritis Versus Non-rheumatoid Arthritis Subjects: Results from a Population-based Study
Overview
Affiliations
Objective: To examine lipid profiles among statin-naive patients with rheumatoid arthritis (RA) and those without RA before and after the initiation of statins.
Methods: Information regarding lipid measures and statin use was gathered in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria first met between January 1, 1988 and January 1, 2008) and in a cohort of non-RA subjects from the same underlying population. Only patients with no prior history of statin use were included.
Results: The study included 161 patients with RA (mean age 56.3 years, 57% female) and 221 non-RA subjects (mean age 56.0 years, 66% female). Prior to the start of statins, the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol were lower in the RA versus the non-RA cohort (P < 0.001 and P = 0.003, respectively). The absolute and percentage change in LDL cholesterol after at least 90 days of statin use tended to be smaller in the RA versus the non-RA cohort (P = 0.03 and P = 0.09, respectively). After at least 90 days of statin use, patients with RA were less likely to achieve therapeutic goals for LDL cholesterol than the non-RA subjects (P = 0.046). Increased erythrocyte sedimentation rate (ESR) at baseline (odds ratio 0.47, 95% confidence interval 0.26-0.85) was associated with lower likelihood of achieving therapeutic LDL goals.
Conclusion: Patients with RA had lower total cholesterol and LDL cholesterol levels before statin initiation and lower likelihood of achieving therapeutic LDL goals following statin use than the non-RA subjects. Some RA disease characteristics, in particular ESR at baseline, may have an adverse impact on achieving therapeutic LDL goals.
Atherosclerotic vascular disease in the autoimmune rheumatologic woman.
Kurmann R, Mankad R Clin Cardiol. 2018; 41(2):258-263.
PMID: 29480591 PMC: 6489857. DOI: 10.1002/clc.22916.
The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis.
Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas G Front Med (Lausanne). 2018; 5:24.
PMID: 29473041 PMC: 5809441. DOI: 10.3389/fmed.2018.00024.
Restrepo J, del Rincon I, Molina E, Battafarano D, Escalante A J Clin Rheumatol. 2017; 23(3):144-148.
PMID: 28277344 PMC: 5364043. DOI: 10.1097/RHU.0000000000000502.
Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment.
Lazurova I, Tomas L Clin Rev Allergy Immunol. 2016; 52(3):323-332.
PMID: 27342458 DOI: 10.1007/s12016-016-8566-3.
Lipid and Metabolic Changes in Rheumatoid Arthritis.
McGrath C, Young S Curr Rheumatol Rep. 2015; 17(9):57.
PMID: 26210510 DOI: 10.1007/s11926-015-0534-z.